Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Filgrastim 7Peripheral Blood Stem Cell Transplantation 4Melphalan 4Etoposide 4Carboplatin 4Busulfan 4Ifosfamide 3Granulocyte Colony-Stimulating Factor 3tanespimycin 2Thiotepa 2Temozolomide 2Mesna 2Docetaxel 2Cyclophosphamide 2trioctyl phosphine oxide 1temsirolimus 1sargramostim 1pegfilgrastim 1omburtamab I-131 1montanide ISA 51 1ixabepilone 1ganitumab 1entinostat 1cixutumumab 1amino-acid, glucose, and electrolyte solution 1alvocidib 1aldesleukin 1Valproic Acid 1Transplantation 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors, Primitive, Peripheral × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡